In need of medication

14 June 2007 By Pierre Briancon

The French drug maker lost E6bn, or 6.5%, of its market cap after a panel said its proposed antiobesity drug is too risky to recommend. It looks like a lost blockbuster. With a weak strategy and two big shareholders on the way out, Sanofi could become an acquisition target. The French drug maker lost E7bn, or 8%, of its market cap after a panel said its proposed antiobesity drug is too risky to recommend.

This content is for Subscribers only

To access full Breakingviews.com content you must be a subscriber. Please use the following link to request a trial.

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)